Literature DB >> 9292789

Osteoclastogenesis in iliac bone marrow of patients with rheumatoid arthritis.

Y Toritsuka1, N Nakamura, S B Lee, J Hashimoto, N Yasui, K Shino, T Ochi.   

Abstract

OBJECTIVE: To investigate osteoclastogenesis in bone marrow cells from patients with various pathogenic backgrounds known to induce osteoporosis, to identify specific factors that may cause generalized osteoporosis in patients with rheumatoid arthritis (RA).
METHODS: Bone marrow blood was obtained from 59 women, 36 with RA and 23 without RA. Patients with RA were classified as severe (26) and mild RA (10: 5 patients with and 5 without corticosteroid therapy). The non-RA subjects were divided into 3 groups, premenopausal (7), menopausal (8), and elderly (8). As a marker of bone resorption, the pyridinoline crosslinked telopeptide domain of type I collagen (ICTP) concentration in the bone marrow supernatant was measured by radioimmunoassay. The bone marrow cells were cultured 14 days in the presence or absence of autologous bone marrow supernatant; then the number of tartrate resistant acid phosphatase positive multinucleated cells (TRAP positive MNC) was counted as an indicator of osteoclastogenesis.
RESULTS: ICTP concentration of the bone marrow supernatant and the number of TRAP positive MNC showed remarkable enhancement in some patients with severe RA, but these features were not observed in the 3 control groups.
CONCLUSION: Increased bone resorption and enhanced osteoclastogenesis were specifically observed in the iliac bone marrow of patients with RA, especially those with severe RA. These phenomena can be considered to accompany generalized osteoporosis in RA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9292789

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis.

Authors:  Nathalie Saidenberg-Kermanac'h; Natacha Bessis; Delphine Lemeiter; Marie-Christine de Vernejoul; Marie-Christophe Boissier; Martine Cohen-Solal
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

2.  Hypercalcemia in rheumatoid arthritis: relationship with disease activity and bone metabolism.

Authors:  Peter Oelzner; Gabriele Lehmann; Thorsten Eidner; Sybille Franke; Andreas Müller; Gunter Wolf; Gert Hein
Journal:  Rheumatol Int       Date:  2006-01-11       Impact factor: 2.631

3.  Tartrate resistant acid phosphatase (TRAP) positive cells in rheumatoid synovium may induce the destruction of articular cartilage.

Authors:  H Tsuboi; Y Matsui; K Hayashida; S Yamane; M Maeda-Tanimura; A Nampei; J Hashimoto; R Suzuki; H Yoshikawa; T Ochi
Journal:  Ann Rheum Dis       Date:  2003-03       Impact factor: 19.103

4.  Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction.

Authors:  Kosuke Ebina; Atsunori Fukuhara; Wataru Ando; Makoto Hirao; Tadashi Koga; Kazuya Oshima; Morihiro Matsuda; Kazuhisa Maeda; Tadashi Nakamura; Takahiro Ochi; Iichiro Shimomura; Hideki Yoshikawa; Jun Hashimoto
Journal:  Clin Rheumatol       Date:  2008-12-16       Impact factor: 2.980

5.  Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis.

Authors:  Christopher T Ritchlin; Sally A Haas-Smith; Ping Li; David G Hicks; Edward M Schwarz
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

Review 6.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

7.  Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover.

Authors:  P Oelzner; S Franke; G Lehmann; T Eidner; A Müller; G Wolf; G Hein
Journal:  Clin Rheumatol       Date:  2007-05-31       Impact factor: 2.980

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.